PRODUCT INFORMATION

Name of the Medicine

Active ingredient: zopiclone
Chemical name: 6-(5-chloro-2-pyridyl)-6,7-dihydro-7-oxo-5H-pyrrolo[3,4-b]pyrazin-5-yl-4-methylpiperazine-1-carboxylate

Structural formula:

![Structural formula of zopiclone]

Molecular formula: C_{17}H_{17}ClN_{6}O_{3}  
Molecular weight: 388.8  
CAS Registry no.: 43200-80-2

Description

Zopiclone is a fine white or slightly cream crystalline powder with a melting point of 176° to 178°C. It is practically insoluble in acetone, soluble in dimethyl formamide and hydrochloric acid 0.1 N and freely soluble in chloroform and dichloromethane.

Each Imrest tablet contains 7.5 mg of zopiclone and the following excipients: lactose anhydrous, calcium hydrogen phosphate anhydrous, maize starch, povidone, magnesium stearate and Opadry White Y-1-7000. The tablets are gluten free.

Pharmacology

Zopiclone, a cyclopyrrolone derivative, is a short-acting hypnotic. It belongs to a novel chemical class which is structurally unrelated to existing hypnotics. The pharmacological profile of zopiclone is similar to that of the benzodiazepines.

In sleep laboratory studies of 1 to 21 day duration in humans, zopiclone reduced sleep latency, increased the duration of sleep and decreased the number of nocturnal awakenings. Zopiclone delayed the onset of rapid eye movement (REM) sleep but did not reduce consistently the total duration of REM periods. The duration of stage 1 sleep was shortened and the time spent in stage 2 sleep increased. In most studies, stage 3 and 4
sleep tended to be increased, but no change and actual decreases have also been observed. The effect of zopiclone on stage 3 and 4 sleep differs from that of the benzodiazepines, which suppress slow wave sleep. The clinical significance of this finding is not known.

**Pharmacokinetics**

*Absorption.* Zopiclone is rapidly absorbed and distributed after oral administration, the median $T_{\text{max}}$ being 1 hour (range 0.5 – 4 hours). A study of 16 healthy volunteers receiving a single dose of zopiclone 7.5 mg intravenously demonstrated the apparent volume of distribution of zopiclone to be $104 \pm 15.5$ L.

*Distribution and Metabolism.* Autoradiographic studies in the rat showed rapid distribution into the blood and peak tissue levels at 0.5 hours in the liver, small intestine, stomach, kidneys and adrenals. After 24 hours the total residual radioactivity in the body of the rat was 8%.

The bioavailability of the 7.5 mg tablets in humans is $76.3 \pm 9.6\%$. An hepatic first-pass effect has been demonstrated.

In fresh human plasma, zopiclone is approximately 45% protein bound in the 25 to 100 nanogram/mL concentration range.

Zopiclone is extensively and rapidly metabolised by the liver. A large number of metabolites have been isolated and characterised, with the two major ones being the N-oxide, produced by oxidation of the piperazine nitrogen, and the N-desmethyl, produced by oxidative demethylation of the N-methyl piperazine.

Only the N-oxide analogue has weak pharmacological activity.

*Elimination & Excretion.* Zopiclone is rapidly eliminated, mainly by means of hepatic metabolism. The elimination half-life after a single oral dose is $5.57 \pm 1.4$ hours. The elimination half-life for the N-oxide metabolite is $4.44 \pm 0.66$ hours and that for the N-desmethyl metabolite is $7.28 \pm 0.49$ hours.

Renal clearance is $13.9 \pm 7.0$ mL/minute which further shows that the major elimination pathway is by hepatic metabolism.

The amount of renal excretion is also low: unchanged zopiclone 3.6%, the N-oxide metabolite 11.4% and the N-desmethyl metabolite 13.4%.

*Use in the elderly.* In elderly patients, the absolute bioavailability is increased (94% versus 77% in young subjects) and the elimination half-life prolonged (approximately 7 hours).

*Impaired hepatic function.* In patients with hepatic insufficiency, the elimination half-life is prolonged (11.9 hours) and the time to peak plasma levels is delayed (3.5 hours).

*Impaired renal function.* In patients with mild to moderate renal insufficiency, the pharmacokinetics of zopiclone are not altered. Haemodialysis does not appear to increase the plasma clearance of the drug.

**Indications**

Short-term treatment of insomnia (two to four weeks).

**Contraindications**

Known hypersensitivity to zopiclone or any excipient.

Myasthenia gravis.
Severe impairment of respiratory function.

Acute cerebrovascular accident.

Sleep apnoea syndrome.

Severe hepatic insufficiency.

Imrest is contraindicated in Children.

Precautions

Prolonged use of hypnotics is not recommended, especially in the elderly.

Use in children. The safe and effective dose of Imrest in children and adolescents under 18 years of age has not been established (see Contraindications).

Use in elderly or debilitated patients. Such patients may be particularly susceptible to the sedative effects of zopiclone and associated giddiness, ataxia and confusion, which may increase the possibility of a fall (see Dosage and Administration).

Effect on ability to drive or operate machinery. As with all patients taking CNS depressant medications, patients receiving zopiclone should be warned not to operate dangerous machinery or motor vehicles until it is known that they do not become drowsy after zopiclone therapy. Abilities may be impaired on the day following use.

It has been reported that the risk that zopiclone adversely affects driving ability is increased by concomitant intake of alcohol. Therefore driving is not recommended after the concomitant intake of zopiclone and alcohol.

Patients should be advised that their tolerance for alcohol and other CNS depressants will be diminished and that these medications should be either eliminated or given in reduced dosage in the presence of zopiclone.

Dependence and withdrawal. Experiments in monkeys have shown intermediate withdrawal signs at doses of 16 to 32 mg/kg orally twice daily. A risk of withdrawal phenomenon after abrupt discontinuation of zopiclone following prolonged use in patients cannot be excluded. It is therefore recommended that after prolonged use the dose should be decreased gradually and the patient advised about such a possibility.

Zopiclone should be prescribed for short periods only (2 to 4 weeks). Continuous long-term use is not recommended, especially in the elderly. There have been reports of withdrawal symptoms and difficulty in stopping treatment after long-term therapy.

Risks of dependence or abuse increase with: dose and duration of treatment; history of alcohol and/or drug abuse; and use with alcohol or other psychotropics.

Once physical dependence has developed, abrupt termination of treatment will be accompanied by withdrawal symptoms.

Renal insufficiency. Treatment should be initiated at a dose of 3.75 mg and, if necessary, should be carried out at 7.5 mg. Zopiclone is removed by dialysis.

Hepatic insufficiency. In patients with severe hepatic insufficiency (serum albumin less than 30 g/L or presence of gross oedema), the elimination of zopiclone may be significantly reduced.

Treatment should be initiated at a dose of 3.75 mg and, if necessary, should be carried out at 7.5 mg.
Respiratory insufficiency. Caution should be exercised in treating patients with chronic respiratory insufficiency. Treatment should be initiated at a dose of 3.75 mg and, if necessary, should be carried out at 7.5 mg.

Hormonal systems. Treatment of rats with zopiclone increases hepatic thyroid hormone metabolism of T4, resulting in increases in thyroid stimulating hormone (TSH) and T3 levels and decreases in T4 levels. It is suggested that zopiclone not be administered to individuals with impaired thyroid hormone homoeostatic mechanisms or with conditions linked to hormonal imbalances.

Depression, psychosis and schizophrenia. As with other hypnotics, zopiclone does not constitute a treatment of depression and may even mark its symptoms. Caution should be exercised if zopiclone is prescribed to depressed patients, including those with latent depression, particularly when suicidal tendencies may be present and protective measures may be required.

Abuse. Caution must be exercised in administering zopiclone to individuals known to be addiction prone or those whose history suggests they may increase the dosage on their own initiative.

Rebound Insomnia. A transient syndrome whereby the symptoms that led to treatment with sedative-hypnotic agents recur in an enhanced form, may occur on withdrawal of hypnotic treatment. Since the risk of such a phenomena is greater after abrupt discontinuation of Imrest, especially after prolonged treatment, it is, therefore, recommended to decrease the dosage gradually and to advise the patient accordingly (see Adverse Effects).

Amnesia. Anterograde amnesia may occur, especially when sleep is interrupted or when retiring to bed is delayed after the intake of the tablet.

To reduce the possibility of anterograde amnesia, patients should ensure that:

- they take the tablet strictly when retiring for the night
- they are able to have a full night's sleep.

Epilepsy. Patients with a history of seizures should not be abruptly withdrawn from any CNS depressant drug, including zopiclone.

Somnambulism and associated behaviours. Sleepwalking and other associated behaviours such as ‘sleep driving’, preparing and eating food, or making phone calls with amnesia for the even, have been reported in patients who have taken zopiclone and were not fully awake. The use of alcohol and other CNS-depressants with zopiclone appears to increase the risk of such behaviours, as does the use of zopiclone at doses exceeding the maximum recommended dose. Discontinuation of zopiclone would be strongly considered for patients who report such behaviours (see Interactions with other Medicines: Alcohol and Adverse Effects).

Other psychiatric and paradoxical reactions. Other psychiatric and paradoxical reactions have been reported (see Adverse Effects).

Carcinogenicity and Mutagenicity

Treatment with zopiclone by dietary administration for two years increased the incidence of thyroid carcinomas in male rats dosed with 100 mg/kg/day and increased the incidence of mammary carcinoma in female rats dosed with 100 mg/kg/day, probably due to interference with thyroid hormone and 17β-oestradiol metabolism. Studies with mice treated with zopiclone at dietary doses up to 100 mg/kg/day showed no evidence of drug-related carcinogenicity.
Genotoxicity studies, using a standard battery of tests, showed no evidence of gene mutations or chromosomal damage.

**Effects on Fertility**

Zopiclone has been shown to severely reduce fertility in male rats treated with 50 mg/kg/day or greater. The significance of this finding for humans is not known.

**Use in Pregnancy (Category C)**

Insufficient data are available on Imrest to assess its safety during human pregnancy and lactation, therefore the use of Imrest during pregnancy is not recommended. Studies in animals have not shown evidence of an increased occurrence of foetal damage. However, zopiclone has been shown to cross the placenta and increase postnatal mortality in rats given 10 mg/kg/day and above. Although the significance of this for humans is not known, it is likely that zopiclone may be harmful to the neonate. If zopiclone is prescribed to a woman of childbearing potential, she should be warned to contact her doctor regarding discontinuation of the product if she intends to become or suspects she is pregnant.

Moreover, if zopiclone is used during the last three months of pregnancy or during labour, due to the pharmacological action of the product, effects on the neonate, such as hypothermia, hypotonia and respiratory depression can be expected.

**Use in Lactation**

Zopiclone and/or its metabolites are excreted in breast milk, therefore use in breastfeeding mothers is not recommended.

**Interactions with other Medicines**

*Alcohol.* Concomitant intake with alcohol is not recommended. The sedative effect of Imrest may be enhanced when the product is used in combination with alcohol.

*CNS Depressants.* Additive CNS depressant effects should be expected if zopiclone is administered concomitantly with other medications which themselves produce CNS depression, e.g. barbiturates, benzodiazepines, alcohol, sedatives, tricyclic antidepressants, non-selective monoamine oxidase inhibitors (MAOIs), phenothiazines and other antipsychotics, skeletal muscle relaxants, antihistamines, narcotic analgesics, anaesthetics, neuroleptics, anxiolytics, antiepileptics (see Precautions).

*Other.* Erythromycin has been reported to significantly increase zopiclone concentrations at 30 minutes and 1 hour after ingestion of zopiclone. The total area under the curve (AUC) of zopiclone increased by 80% in 10 healthy volunteers. Accelerated absorption of zopiclone in the presence of erythromycin may lead to faster hypnotic effects.

Plasma levels of zopiclone may be increased when co-administered with CYP3A4 inhibitors such as erythromycin, clarithromycin, ketoconazole, itraconazole, and ritonavir.

Plasma levels of zopiclone may be decreased when co-administered with CYP3A4 inducers, such as rifampicin, carbamazepine, phenobarbital, phenytoin, and St. John’s wort.
Adverse Effects

The side-effect most commonly seen in clinical trials is taste alteration (bitter taste).

More Common Effects:

**Gastrointestinal.** Bitter taste, dry mouth.

**Nervous System.** Drowsiness, headaches, fatigue.

Less Common Effects:

**Gastrointestinal.** Heartburn, constipation, diarrhoea, nausea, coated tongue, bad breath, anorexia or increased appetite, vomiting, epigastric pains, dyspepsia.

**Nervous system.** Agitation, anxiety, loss of memory including retrograde amnesia, anterograde amnesia, confusion, dizziness, weakness, somnolence, asthenia, feeling of drunkenness, euphoria, depression, coordination abnormality, hypotonia, speech disorder, hallucinations (auditory and visual), behavioural disorders, aggression, tremor, rebound insomnia, nightmares, irritability, inappropriate behaviour possibly associated with amnesia, sleepwalking (see Precautions: Somnambulism and Associated Behaviours).

Withdrawal syndrome has been reported upon discontinuation (see Precautions). Withdrawal symptoms vary and may include rebound insomnia, anxiety, tremor, sweating, agitation, confusion, headache, palpitations, tachycardia, delirium, nightmares, hallucinations, and irritability. In very rare cases, seizures may occur.

**Cardiovascular.** Palpitations in elderly patients.

**Skin.** Urticaria, tingling.

**Allergic or cutaneous.** Pruritus, rash. Angioedema and/or anaphylactic reactions have been reported very rarely.

**Miscellaneous.** Blurred vision, micturition, mild to moderate increases in serum transaminases and/or alkaline phosphatase have been reported very rarely.

**Reproductive.** Impotence, ejaculation failure.

Dosage and Administration

**Adults.** One tablet (7.5 mg) by oral administration shortly before retiring for a maximum of 2 to 4 weeks. This dose should not be exceeded. Depending on clinical response, the dose may be lowered to 3.75 mg.

Zopiclone is not recommended for long-term use (i.e. periods of more than 4 weeks). If used for long periods, treatment should be withdrawn gradually (see Precautions, Dependence and withdrawal).

**Elderly.** In elderly and/or debilitated patients an initial dose of 3.75 mg is recommended. The dose may be increased to a maximum of 7.5 mg if the starting dose does not offer adequate therapeutic effect, but in clinical trials, 25% of elderly patients treated with zopiclone experienced CNS side effects at the higher dose. Zopiclone should be used with caution in these patients (see Precautions).

**Children.** Zopiclone is contraindicated in children. Dosage has not been established.

**Impaired hepatic function.** The recommended dose is 3.75 mg depending on acceptability and efficacy. Up to 7.5 mg may be used with caution in appropriate cases.
Alternative therapy. For long-term treatment of insomnia, alternative non-pharmacological methods should be considered. Effective practical management of insomnia must respond to the presenting characteristics of the complaint. Giving accurate information is a form of treatment; there is benefit in discussing some simple facts with the patient and relating them to the problem, thereby assisting the patient to place the sleep problem in its context. Sleep hygiene such as reduction of caffeine intake, should be exercised. Programs designed to establish an optimal sleeping pattern for the patient may also be useful as are relaxation techniques designed to assist the patient to deal with tension and intrusive thoughts in bed.

Overdosage

Symptoms. Overdose of zopiclone can be manifested by varying degrees of CNS depression ranging from drowsiness to coma according to the quantity ingested. In mild cases, symptoms include drowsiness, confusion and lethargy. In more severe cases, symptoms may include ataxia, hypotonia, hypotension, respiratory depression and coma. Overdosage could be life threatening when combined with other CNS depressants, including alcohol. Other risk factors, such as the presence of concomitant illness and the debilitated state of the patient, may contribute to the severity of symptoms and very rarely can result in fatal outcome.

Treatment. Symptomatic and supportive treatment in an adequate clinical environment is recommended, attention should be paid to respiratory and cardiovascular function. Activated charcoal is only useful when performed soon after ingestion. Haemodialysis is of no value, due to large volumes of distribution of zopiclone. Flumazenil may be useful as an antidote. As in the management of overdosage with any medication, it should be borne in mind that multiple agents may have been taken.

In cases of overdosage, it is advisable to contact the Poisons Information Centre (13 11 26 – Australia) for advice on the management of overdose.

Presentation and Storage Conditions

Imrest: zopiclone 7.5 mg, white, film coated, oval tablet embossed with “Z” breakline “Z” on one side and “7.5” on the other; 30 tablet blister pack.

Store below 25°C.

Poison Schedule of the Medicine

S4 Prescription Only Medicine

Name and Address of the Sponsor

Alphapharm Pty Limited

Chase Building 2

Wentworth Park Road

Glebe NSW 2037

ABN 93 002 359 739

www.alphapharm.com.au
Date of Most Recent Amendment

Approved by the Therapeutic Goods Administration on 24 November 2004.

Date of most recent amendment: 08 May 2007.